Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?
Sharon R. Sznitman, Barbara Broers, Reto Auer, Kali Tal
Int J Drug Policy July 26, 2024 DOI: 10.1016/j.drugpo.2024.104521 via PubMed
Summary
AI-generated from the abstractThe article argues that the potential harms of psychedelic-assisted therapy must be taken seriously, focusing on how to prevent or mitigate risks to vulnerable patients. It discusses the need for robust safety protocols, clinical safeguards, and best practices to protect patient well-being. The authors emphasize that without careful risk management and harm reduction strategies, vulnerable individuals may face adverse outcomes. The work calls for integrating patient protection measures into therapeutic protocols and treatment standards to ensure safe clinical practice in psychedelic medicine.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelic medicine Psychedelic treatment Patient safety |
| Citations | 1 |
| Key finding | The article argues that preventing or mitigating risks to vulnerable patients requires serious attention to potential harms through robust safety protocols and clinical safeguards in psychedelic-assisted therapy. |
Abstract
Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?